This trial aims to evaluate the safety and effectiveness of a targeted cancer therapy in combination with a type of chemotherapy in multiple myeloma patients that have got worse or not responded to at least one prior treatmentA Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Exclusion

• Has a pre-existing condition that is contraindicated including.

  • Non-secretory or oligo-secretory MM
  • Active plasma cell leukemia.
  • Waldenström's macroglobulinemia.
  • Primary amyloidosis.
  • POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).
  • Active hepatitis B or C infection based on screening blood testing.
  • Known active Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
  • Significant cardiovascular disease.
  • Major surgery within 4 weeks prior to first dose.
  • Acute infections requiring antibiotic, antifungal or antiviral therapy within14 days prior to first dose.
  • Peripheral neuropathy ≥ Grade 3 or ≥ Grade 2 with pain within 2 weeks prior to first dose.
  • Uncontrolled diabetes or uncontrolled hypertension within 14 days prior to first dose.
  • Any other medical condition that, in the opinion of the Investigator, would adversely affect the participant's participation in the study.
• History of other active malignancies, including myelodysplastic syndrome (MDS), within the past 3 years prior to study entry Other protocol defined inclusion/exclusion criteria could apply